Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽호신 | - |
dc.contributor.author | 이기택 | - |
dc.contributor.author | 박철기 | - |
dc.contributor.author | 김진욱 | - |
dc.contributor.author | 홍용길 | - |
dc.contributor.author | 강석구 | - |
dc.contributor.author | 김정훈 | - |
dc.contributor.author | 설호준 | - |
dc.contributor.author | 정태영 | - |
dc.contributor.author | 장종희 | - |
dc.contributor.author | 유헌 | - |
dc.contributor.author | 황정현 | - |
dc.contributor.author | 김세혁 | - |
dc.contributor.author | 박봉진 | - |
dc.contributor.author | 황선철 | - |
dc.contributor.author | 김민수 | - |
dc.contributor.author | 김선환 | - |
dc.contributor.author | 김은영 | - |
dc.contributor.author | Ealmaan Kim | - |
dc.contributor.author | 김해유 | - |
dc.contributor.author | 고영초 | - |
dc.contributor.author | 윤환중 | - |
dc.contributor.author | 윤지혜 | - |
dc.contributor.author | 김주영 | - |
dc.contributor.author | 이병길 | - |
dc.contributor.author | 이승훈 | - |
dc.date.accessioned | 2021-08-12T01:27:36Z | - |
dc.date.available | 2021-08-12T01:27:36Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 2005-3711 | - |
dc.identifier.issn | 1598-7876 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/14130 | - |
dc.description.abstract | Objective : To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). Methods : A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 mg/m2/day) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed. Results : TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (≥grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p<0.05). Overall survival (OS) was apparently differed by the patient’s histology, as AOA patients survived a median OS of 18.0 months while AO patients did not reach median OS at median follow-up of 11.5 months (range 2.7-65 months). Good performance status of Eastern Cooperative Oncology Group 0 and 1 showed prolonged OS (p<0.01). Conclusion : For recurrent AO/AOA after surgery followed by radiation therapy, TMZ could be recommended as a salvage therapy at the estimated efficacy equal to procarbazine, lomustine, and vincristine (PCV) chemotherapy at first relapse. For patients previously treated with PCV, TMZ is a favorable therapeutic option as 2nd line salvage chemotherapy with an acceptable toxicity rate. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한신경외과학회 | - |
dc.title | Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma | - |
dc.title.alternative | Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.bibliographicCitation | Journal of Korean Neurosurgical Society, v.54, no.6, pp 489 - 498 | - |
dc.citation.title | Journal of Korean Neurosurgical Society | - |
dc.citation.volume | 54 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 489 | - |
dc.citation.endPage | 498 | - |
dc.identifier.kciid | ART002097835 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Anaplastic oligodendroglioma · Anaplastic oligoastrocytoma · Chemotherapy · Recurrence · Temozolomide. | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.